A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma.

Trial Profile

A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Perifosine (Primary)
  • Indications Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jun 2010 Last checked against National Cancer Institute of Canada.
    • 11 Aug 2009 Lead trial centre and lead investigators added as reported by ClinicalTrials.gov.
    • 21 Mar 2006 Status changed from suspended to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top